Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by Marie Tauber
Based on 12 articles published since 2010
(Why 12 articles?)
||||

Between 2010 and 2020, M. Tauber wrote the following 12 articles about Psoriasis.
 
+ Citations + Abstracts
1 Guideline [French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults]. 2019

Amatore, F / Villani, A-P / Tauber, M / Guillot, B / Viguier, M / Anonymous1941051. ·Service de dermatologie, hôpital de la Timone, université Aix-Marseille, 13005 Marseille, France. · Service de dermatologie, hôpital Édouard-Herriot, université de Lyon, 69003 Lyon, France. · Service de dermatologie et d'allergologie, hôpital Larrey, université de Toulouse, 31400 Toulouse, France. · Service de dermatologie, CHU de Montpellier, université de Montpellier, 54090 Montpellier, France. · Service de dermatologie, hôpital Robert-Debré, université de Reims, 51092 Reims, France. Electronic address: mviguier@chu-reims.fr. ·Ann Dermatol Venereol · Pubmed #31208735.

ABSTRACT: AIM: These guidelines for the treatment of psoriasis have been developed by the Psoriasis Research Group of the French Society of Dermatology with the aim of providing updated decision-making algorithms for the systemic treatment of adult patients with moderate-to-severe psoriasis. METHODS: Our algorithms were generated after rigorous evaluation of existing guidelines on the treatment of psoriasis and of publications concerning new systemic treatments, not yet incorporated into existing guidelines. A total of nine existing guidelines and 53 publications related to new systemic treatments were found to meet our criteria for use in generating the algorithms. RESULTS: We propose two new algorithms to assess therapeutic response, both of which incorporate emerging criteria for evaluating treatment goals. Updated therapeutic strategy algorithms, incorporating both established and new systemic therapies, were also generated for the treatment of plaque psoriasis and psoriatic arthritis, together with recommendations for the treatment of particular forms of psoriasis and treatment of patients with comorbidities.

2 Guideline French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. 2019

Amatore, F / Villani, A-P / Tauber, M / Viguier, M / Guillot, B / Anonymous5670980. ·Dermatology Department, Timone Hospital, Aix-Marseille University, Marseille, France. · Dermatology Department, Edouard Herriot Hospital, Lyon University, Lyon, France. · Dermatology and Allergology Department, Larrey Hospital, Toulouse University, Toulouse, France. · Dermatology Department, Robert Debré Hospital, Reims University, Reims, France. · Centre de Preuves en Dermatologie, Paris, France. · Dermatology Department, CHU of Montpellier, Montpellier University, Montpellier, France. ·J Eur Acad Dermatol Venereol · Pubmed #30793796.

ABSTRACT: These guidelines were developed by the psoriasis research group of the French Society of Dermatology with the aim of providing updated decision-making algorithms for the systemic treatment of adult patients with moderate-to-severe psoriasis. Our algorithms were generated after rigorous evaluation of existing guidelines on the treatment of psoriasis and of publications concerning new systemic treatments, not yet incorporated into existing guidelines. A total of nine existing guidelines and 53 publications related to new systemic treatments were found to meet our criteria for use in the generation of the algorithms. We have proposed two new algorithms to assess therapeutic responses, both of which incorporate emerging criteria for evaluating treatment goals. Updated therapeutic strategy algorithms, incorporating both established and new systemic therapies, were also generated for the treatment of plaque psoriasis and psoriatic arthritis, together with recommendations for the treatment of particular forms of psoriasis and treatment of patients with comorbidities.

3 Review IL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases. 2016

Tauber, Marie / Bal, Elodie / Pei, Xue-Yuan / Madrange, Marine / Khelil, Amel / Sahel, Houria / Zenati, Akila / Makrelouf, Mohamed / Boubridaa, Khaled / Chiali, Amel / Smahi, Naima / Otsmane, Farida / Bouajar, Bakar / Marrakchi, Slaheddine / Turki, Hamida / Bourrat, Emmanuelle / Viguier, Manuelle / Hamel, Yamina / Bachelez, Hervé / Smahi, Asma. ·INSERM unit U1163, Imagine Institute, Necker-Enfants Malades Hospital, Paris, France. · Department of Biochemistry, University of Cambridge, Cambridge, UK. · Department of Dermatology, CHU Oran, Oran, Algeria. · Department of Dermatology, CHU Bab El Oued, Bab el Oued, Alger, Algeria. · Central laboratory of Biology, CHU Bab El Oued, Bab el Oued, Alger, Algeria. · Department of Dermatology and the Laboratory of Immunology, Hedi Chaker Hospital, Sfax University, Sfax, Tunisia. · Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris, France. · Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris, France; University Paris-Diderot, Sorbonne Paris Cité, Paris, France. · INSERM unit U1163, Imagine Institute, Necker-Enfants Malades Hospital, Paris, France; Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris, France; University Paris-Diderot, Sorbonne Paris Cité, Paris, France. · INSERM unit U1163, Imagine Institute, Necker-Enfants Malades Hospital, Paris, France. Electronic address: asma.smahi@inserm.fr. ·J Invest Dermatol · Pubmed #27220475.

ABSTRACT: Homozygous or compound heterozygous IL36RN gene mutations underlie the pathogenesis of psoriasis-related pustular eruptions including generalized pustular psoriasis, palmoplantar pustular psoriasis, acrodermatitis continua of Hallopeau, and acute generalized exanthematous pustular eruption. We identified two unreported IL36RN homozygous mutations (c.41C>A/p.Ser14X and c.420_426del/p.Gly141MetfsX29) in patients with familial generalized pustular psoriasis. We analyzed the impact of a spectrum of IL36RN mutations on IL-36 receptor antagonist protein by using site-directed mutagenesis and expression in HEK293T cells. This enabled us to differentiate null mutations with complete absence of IL-36 receptor antagonist (the two previously unreported mutations, c.80T>C/p.Leu27Pro, c.28C>T/p.Arg10X, c.280G>T/p.Glu94X, c.368C>G/p.Thr123Arg, c.368C>T/p.Thr123Met, and c.227C>T/p.Pro76Leu) from mutations with decreased (c.95A>G/p.His32Arg, c.142C>T/p.Arg48Trp, and c.308C>T/p.Ser113Leu) or unchanged (c.304C>T/p.Arg102Trp and c.104A>G/p.Lys35Arg) protein expression. Functional assays measuring the impact of mutations on the capacity to repress IL-36-dependent activation of the NF-κB pathway showed complete functional impairment for null mutations, whereas partial or no impairment was observed for other mutations considered as hypomorphic. Finally, null mutations were associated with severe clinical phenotypes (generalized pustular psoriasis, acute generalized exanthematous pustular eruption), whereas hypomorphic mutations were identified in both localized (palmoplantar pustular psoriasis, acrodermatitis continua of Hallopeau) and generalized variants. These results provide a preliminary basis for genotype-phenotype correlation in patients with deficiency of the IL-36Ra (DITRA), and suggest the involvement of other factors in the modulation of clinical expression.

4 Article Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. 2019

Ferrières, L / Konstantinou, M P / Bulai Livideanu, C / Hegazy, S / Tauber, M / Amelot, F / Paul, C. ·Department of Dermatology, Toulouse University and Larrey Hospital, Toulouse, France. ·Clin Exp Dermatol · Pubmed #31055846.

ABSTRACT: BACKGROUND: There are limited data regarding the long-term continuation with biological therapy for patients with psoriasis. In particular, the reasons for secukinumab discontinuation have not been thoroughly investigated. AIM: To better ascertain the real-life continuation of secukinumab in psoriasis, we conducted a retrospective study to evaluate the incidence, causes and factors of secukinumab discontinuation in patients with psoriasis. METHODS: All patients treated with secukinumab for psoriasis in the Department of Dermatology (Toulouse University and Larrey Hospital, Toulouse, France), between September 2011 and June 2017, were enrolled in the study. RESULTS: Of the 91 patients in the study, 22 (24.2%) discontinued secukinumab. In 14 (15%) patients, the discontinuation was due to loss of efficacy. Two patients stopped treatment because they planned a pregnancy and five patients stopped because of adverse events. A longer disease duration (P = 0.01) and presence of palmoplantar psoriasis (P = 0.01) seem to be predictive factors for treatment failure. Patients reaching 90 or 100% improvement in Psoriasis Area and Severity Index (PASI90 and PASI100, respectively) at weeks 12-16 had a lower risk of long-term treatment discontinuation compared with patients who had less complete clearance (P = 0.04). CONCLUSION: Long-term persistence of secukinumab appears to be good, as only 24.2% (n = 22) of the patients in this study discontinued secukinumab over the follow-up period. Loss of efficacy prompted discontinuation in about 14% of patients by the 2-year follow-up. Persistence appears to be lower in patients with palmoplantar psoriasis and in patients previously exposed to many systemic treatments. Optimal therapeutic response at 12-16 weeks as defined by reaching PASI90-100 seems to be predictive of long-term treatment persistence.

5 Article Compounded topical preparations in plaque psoriasis: Still a place for it in 2018? 2019

Börjesson, Clothilde / Guinard, Elisabeth / Tauber, Marie / Konstantinou, Maria-Polina / Livideanu, Cristina B / Mazereeuw-Hautier, Juliette / Meyer, Nicolas / Paul, Carle. ·Dermatologie, Université Paul Sabatier, CHU Toulouse, Toulouse, France. · Onco-Dermatologie, Institut Universitaire du Cancer Toulouse, Toulouse, France. ·Dermatol Ther · Pubmed #30387924.

ABSTRACT: Compounded topical preparations (CTP) were used to treat psoriasis until the last century and have disappeared from guidelines. The present authors report two severe psoriasis patients who were treated with CTP. A man had psoriasis with a PASI of 23 and a body surface area (BSA) of 43%. He had been using daily for several weeks a CTP including minoxidil, clobetasol propionate and hydroxyprogesterone formulated in an alcohol based vehicle. A woman suffered from psoriasis with an annular inflammatory pattern and a central healing. The PASI was 20 and the BSA was 30%. She had been using a CTP daily for 4 months including resorcinol, salicylic acid, 0.05% tretinoin cream, bethamethasone dipropionate cream. Until the 1970s, the dermatological textbooks recommended to treat severe psoriasis with CTP. Nowadays, CTP are considered outdated because of the large therapeutic armamentarium. The stability and benefit risks of the CTP used here were not documented. The use of CTP in psoriasis should be regulated and must be evidence based. Strict protocol and stability evaluation for preparations must be confirmed prior to compounding.

6 Article Partial clinical response to anakinra in severe palmoplantar pustular psoriasis. 2014

Tauber, M / Viguier, M / Alimova, E / Petit, A / Lioté, F / Smahi, A / Bachelez, H. ·Université Paris Diderot-Sorbonne, Paris Cité, Department of Dermatology, Hôpital Saint-Louis, APHP, 1 avenue Claude-Vellefaux, 75475 Cedex 10, Paris, France; Laboratory of genetics of autoinflammatory diseases, Université Paris Diderot-Sorbonne, Paris Cité, Institut Imagine, Hôpital Necker-Enfants Malades, Paris, France. ·Br J Dermatol · Pubmed #24684162.

ABSTRACT: BACKGROUND: Palmoplantar pustular psoriasis is a clinical psoriasis variant characterised by a high impact on quality of life and poor response to biologics approved for plaque type psoriasis.The recombinant interleukin-1 (IL-1) receptor antagonist anakinra has been recently used for the treatment of isolated refractory cases of generalised pustular psoriasis with contrasted results. OBJECTIVES: To report the clinical response in two patients treated with anakinra as salvage therapy in two patients with severe palmoplantar pustular psoriasis refractory to currently available antipsoriatic systemic therapies. METHODS: Anakinra was given subcutaneously at the daily dose of 100 mg, and clinical response was evaluated using the palmoplantar psoriasis area and severity index (PPPASI). RESULTS: Only partial and transient responses were observed in both patients, who had to stop anakinra due to lack of efficacy and to side effects. CONCLUSION: Anakinra appears to provide only partial clinical improvement in refractory palmoplantar pustular psoriasis. Prospective clinical studies on larger populations are warranted to investigate more accurately both efficacy and safety of IL-1-inhibiting strategies in pustular psoriasis.

7 Minor Impact of the French guidelines on the prescribing habits of systemic treatments for moderate-to-severe psoriasis. 2020

Villani, A P / Amatore, F / Tauber, M / Guillot, B / Viguier, M / Beylot-Barry, M / Jullien, D / Anonymous2701198. ·Hospices Civils de Lyon, Université Claude Bernard Lyon I, Service de Dermatologie de l'Hôpital Edouard Herriot, Lyon, France. · Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie. · Service de dermatologie, hôpital de la Timone, université Aix-Marseille, 13005, Marseille, France. · Service de dermatologie, et d'allergologie, hôpital Larrey, université de Toulouse, 31400, Toulouse, France. · Service de dermatologie, CHU de Montpellier, université de Montpellier, 54090, Montpellier, France. · Service de dermatologie, hôpital Robert-Debré, Université de Reims- Champagne Ardenne, 51092, Reims, France. · Service de dermatologie, hôpital Saint-André, Université de Bordeaux, 33000, Bordeaux, France. ·J Eur Acad Dermatol Venereol · Pubmed #32396980.

ABSTRACT: We published in 2019 in the Journal of the European Academy of Dermatology and Venereology (JEADV) the first French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults

8 Minor Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. 2019

Hegazy, S / Konstantinou, M P / Bulai Livideanu, C / Tauber, M / Paul, C. ·Department of Dermatology, Hôpital Larrey, Toulouse University, Toulouse, France. ·J Eur Acad Dermatol Venereol · Pubmed #31001858.

ABSTRACT: -- No abstract --

9 Minor Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome. 2019

Bal, Elodie / Lim, Ai Ching / Shen, Min / Douangpanya, Jason / Madrange, Marine / Gazah, Rihab / Tauber, Marie / Beghdadi, Walid / Casanova, Jean Laurent / Bourrat, Emmanuelle / Bachelez, Hervé / Towne, Jennifer E / Smahi, Asma. ·Sorbonne Paris Cité, IMAGINE Institute, Necker Hospital, Enfants-Malades, UMR 1163, Paris-Descartes University, Paris, France. · Inflammation Research and Therapeutic Discovery, Amgen Inc., Seattle, WA, USA. · Clinical Research Unit, APHP Saint-Louis Hospital, Paris, France. · Rockefeller Branch, St. Giles Laboratory of Human Genetics of Infectious Diseases, The Rockefeller University, New York, NY, USA. · Necker Branch, Laboratory of Human Genetics of Infectious Diseases, Sorbonne Paris Cité, IMAGINE Institute, Necker Hospital, Enfants-Malades, UMR 1163, Paris-Descartes University, Paris, France. · Pediatric Hematology-Immunology-Rheumatology Unit, AP-HP, Necker Enfants Malades Hospital, Paris, France. · Sorbonne Paris Cité, Paris Diderot University, Paris, France. · Department of Pediatrics, APHP Robert Debré Hospital, Paris, France. · Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France. · Moved to Janssen Research & Development LLC, San Diego, CA, USA. ·Exp Dermatol · Pubmed #28603914.

ABSTRACT: The identification of loss-of-function mutations of the IL36RN gene encoding the interleukin-36 receptor antagonist (IL-36Ra) in generalized pustular psoriasis (GPP) emphasized the key role of this pathway in skin innate immunity and systemic inflammation. It has been previously shown in vitro that removal of the N-terminal amino acid IL36Ra (M1) is critical to its biological activity, but the in vivo contribution of this processing remains unknown. We report herein a new homozygous (c4G>T, pV2F) missense IL36RN mutation segregating in a family with three GPP-affected patients. The V2F mutation does not alter IL-36Ra protein expression but was devoid of any antagonist activity. Mass spectrometry showed that the V2F IL-36Ra mutant retains its first N-terminal methionine. These results provide the first in vivo demonstration that removal of N-terminal methionine of native IL-36Ra is a mandatory step to reach optimal antagonist activity and to prevent sustained skin and systemic inflammation in humans.

10 Minor Efficacy of ustekinumab in palmoplantar pustulosis. 2018

Hegazy, S / Konstantinou, M P / Bulai Livideanu, C / Tauber, M / Uthurriague, C / Paul, C. ·Department of Dermatology, Hôpital Larrey, Toulouse University, Toulouse, France. ·J Eur Acad Dermatol Venereol · Pubmed #29194805.

ABSTRACT: -- No abstract --

11 Minor Authorship selection in industry-sponsored publications of dermatology clinical trials. 2017

Tauber, M / Paul, C. ·Dermatology Department, Larrey Hospital, Toulouse University, 24 Chemin de Pouvourville, 31059, Toulouse CEDEX 9, France. ·Br J Dermatol · Pubmed #28303566.

ABSTRACT: -- No abstract --

12 Minor Alopecia areata developing during ustekinumab therapy: report of two cases. 2013

Tauber, Marie / Beneton, Nathalie / Reygagne, Pascal / Bachelez, Hervé / Viguier, Manuelle. ·Department of Dermatology. · Department of Dermatology, Centre Hospitalier du Mans, France. · Centre Sabouraud, Hôpital Saint-Louis, Paris VII Denis-Diderot University, 1 avenue Claude-Vellefaux, 75475 Paris Cedex 10, France. ·Eur J Dermatol · Pubmed #24334218.

ABSTRACT: -- No abstract --